Stoke Therapeutics Inc (STOK)
12.02
+0.33
(+2.82%)
USD |
NASDAQ |
May 03, 16:00
12.00
-0.02
(-0.17%)
After-Hours: 20:00
Stoke Therapeutics Enterprise Value: 355.18M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 355.18M |
| May 02, 2024 | 339.90M |
| May 01, 2024 | 333.88M |
| April 30, 2024 | 309.34M |
| April 29, 2024 | 347.77M |
| April 26, 2024 | 373.23M |
| April 25, 2024 | 339.90M |
| April 24, 2024 | 338.51M |
| April 23, 2024 | 319.52M |
| April 22, 2024 | 319.52M |
| April 19, 2024 | 356.57M |
| April 18, 2024 | 338.04M |
| April 17, 2024 | 341.29M |
| April 16, 2024 | 375.09M |
| April 15, 2024 | 363.97M |
| April 12, 2024 | 389.90M |
| April 11, 2024 | 423.71M |
| April 10, 2024 | 389.44M |
| April 09, 2024 | 393.61M |
| April 08, 2024 | 400.55M |
| April 05, 2024 | 380.64M |
| April 04, 2024 | 362.12M |
| April 03, 2024 | 391.99M |
| April 02, 2024 | 404.26M |
| April 01, 2024 | 423.24M |
| Date | Value |
|---|---|
| March 28, 2024 | 423.71M |
| March 27, 2024 | 454.73M |
| March 26, 2024 | 275.07M |
| March 25, 2024 | 99.58M |
| March 22, 2024 | 90.32M |
| March 21, 2024 | 75.97M |
| March 20, 2024 | 75.97M |
| March 19, 2024 | 67.17M |
| March 18, 2024 | 80.13M |
| March 15, 2024 | 94.49M |
| March 14, 2024 | 96.16M |
| March 13, 2024 | 113.15M |
| March 12, 2024 | 103.04M |
| March 11, 2024 | 130.14M |
| March 08, 2024 | 146.21M |
| March 07, 2024 | 149.88M |
| March 06, 2024 | 164.57M |
| March 05, 2024 | 126.00M |
| March 04, 2024 | 113.38M |
| March 01, 2024 | 148.96M |
| February 29, 2024 | 154.01M |
| February 28, 2024 | 164.11M |
| February 27, 2024 | 173.76M |
| February 26, 2024 | 103.96M |
| February 23, 2024 | 71.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-65.45M
Minimum
Oct 27 2023
2.266B
Maximum
Jan 19 2021
555.72M
Average
513.83M
Median
Apr 06 2020
Enterprise Value Benchmarks
| NeuBase Therapeutics Inc | -11.06M |
| iBio Inc | 16.80M |
| Actinium Pharmaceuticals Inc | 182.80M |
| Lixte Biotechnology Holdings Inc | 5.797M |
| Fate Therapeutics Inc | 87.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.96M |
| Revenue (Quarterly) | 2.802M |
| Total Expenses (Quarterly) | 32.39M |
| EPS Diluted (Quarterly) | -0.60 |
| Profit Margin (Quarterly) | -962.1% |
| Earnings Yield | -19.72% |
| Normalized Earnings Yield | -19.72 |